Patients carrying the PNPLA3 polymorphism not only have a higher risk of steatohepatitis and fibrosis, but also have a more than threefold increased risk of HCC (Liu et al., 2014b; Singal et al., 2014). Here, PNPLA3 is linked to hepatocellular carcinoma.